MAYZENT is a sphingosine 1-phosphate (S1P) receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
How to use:
Assessments are required prior to initiating MAYZENT.
Titration is required for treatment initiation.
The recommended maintenance dosage is 2 mg.
Caution & Warnings:
Infections
Progressive Multifocal Leukoencephalopathy (PML)
Macular Edema
Bradyarrhythmia and Atrioventricular Conduction Delays
MAYZENT is a sphingosine 1-phosphate (S1P) receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
How to use:
Assessments are required prior to initiating MAYZENT.
Titration is required for treatment initiation.
The recommended maintenance dosage is 2 mg.
Caution & Warnings:
Infections
Progressive Multifocal Leukoencephalopathy (PML)
Macular Edema
Bradyarrhythmia and Atrioventricular Conduction Delays